The effect of sulphadiazine and trimethoprim (T-S) was 
Introduction
In a critical review of the treatment of non-specific urethritis Simpoulos' suggested that only by comparing the results of treatment with tetracyclines and placebos or other drugs-for instance those outside the antibiotic range and with no suspected side effects-would it be reasonable to form a firm view on the desirability or effectiveness of the treatment. Furthermore, such a comparison should be carried out over a prolonged period of time. ' Tetracyclines and erythromycin are the drugs of choice for the treatment of nongonococcal urethritis (NGU), both in chlamydia-positive and chlamydianegative cases. Neofarma, Helsinki, Finland) or placebo, one tablet twice daily for two weeks. Tablets containing trimethoprim (160 mg) and sulphadiazine (500 mg) or placebo were packed identically and randomised. The code was kept by an independent observer until the trial was completed. The patients were instructed not to have sexual intercourse without the use of a condom until re-examination at two weeks after the end of the treatment. The female partners were examined one to three days after the men, but the treatment of both partners was always started simultaneously.
All the female patients and those male patients with a positive chlamydial culture result initially or with urethral discharge or urethral discomfort or both at follow up were re-examined for the presence of C trachomatis. Before treatment was given all patients were informed that it might not be effective and that further treatment might be necessary. Patients who continued to be chlamydia-positive or to show evidence of urethritis when re-examined were retreated with doxycycline (Doximycin® , Orion) 100 mg twice daily for 10 days. TREATMENT Men A total of 34 men received trimethoprim-sulphadiazine (T-S) and 41 received a placebo (Table I) . Before treatment, C trachomatis had been isolated in 19 (560o) of the former group and in 21 (51 %) of the latter. At re-examination four weeks after the beginning of treatment one of the patients treafed with T-S had not responded to treatment. In the placebo group, 21 treatment failures occurred and 16 patients continued to be chlamydia-positive when reexamined. In five cases of clinical failure after placebo treatment no attempt was made to reisolate C trachomatis at follow up. The difference in effect between T-S and placebo on C trachomatis was highly significant (XI = 19-75, P<0 001). Both of these patients harboured C trachomatis before and after treatment. Acute salpingitis was diagnosed in three (207o) of the 15 chlamydiapositive women treated with placebo. Because of the complications the trial was discontinued at this stage.
RETREATMENT Twenty-three men (three from the group treated with T-S and 20 from the group treated with placebo) who either remained chlamydia-positive or showed clinical failure despite negative culture results were treated with doxycycline. Eleven of these men attended l'"r further follow up, and only one was chlamydia-positive and clinically not cured (Table  II) . The female partner of the only patient with NGU with treatment failure was repeatedly chlamydianegative. Fifteen of the female partners of the male patients treated with doxycycline attended for further follow up and were all chlamydia-negative. The criteria for cured NGU are the eradication of symptoms and signs of urethritis together with a negative culture result for C trachomatis. There is still no general agreement on the length of the followup period after treatment of NGU. Very long followup periods have been advocated by some,'6 but examination months after treatment is unreliable because of high default rates, spontaneous remissions, and reinfections. Furthermore, it is not common practice to re-examine patients with uncomplicated gonorrhoea many months after treatment.
Studies of placebo treatment of infections caused by known pathogens, and with obvious risks of complications, are of doubtful value. Such studies of the treatment of NGU have been carried out previously and have shown placebo treatment to be less effective than active treatment.'7 18 The present study was undertaken to evaluate the difference between placebo and active therapy in a well controlled series with treatment of both partners. The study was indicated because of doubts about the effect of present treatment of NGUI and because the need to treat NGU at all seems to be in question.
The chlamydial isolation rate in men with NGU and in their female partners was high in the present series. The results showed that the combination of trimethoprim and sulphadiazine given for two weeks was effective in treating chlamydial NGU. Compared with the results in the placebo group the difference was statistically highly significant. The treatment of the sexual partner was even more convincing. None of the initially chlamydia-positive women remained culture-positive after active treatment.
The results in the placebo group confirmed the good reproducibility of the isolation technique for C trachomatis, since over 80%7o of the initially chlamydia-positive patients still had positive chlamydial culture results four weeks after the placebo treatment had been started. Conversely, only five initially chlamydia-negative patients were found to be chlamydia-positive after placebo treatment.
The high rate of complications in patients treated with placebo in the present series caused the trial to be discontinued. All the complications occurred in chlamydia-positive patients. The risk of ascending infection in women with cervical chlamydia was unexpected; three out of 15 patients treated with placebo developed acute salpingitis.
Thus the trimethoprim-sulphadiazine combination used in the present study is effective in the treatment of chlamydial urogenital infections provided the sexual partner is treated simultaneously. The cure rate for NGU was higher than with trimethoprimsulphamethoxazole, as reported by Danielsson and Wikstrom.4 However, in their study C trachomatis was not isolated and sexual partners were not treated.
The high incidence of complications in patients treated with placebo in the present series serves as a clear warning against future placebo trials in chlamydial infections.
